Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.55 |
| ▸ | CA2 | P00918 | 4/20 | 0.55 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | STS | P08842 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14679461 | 0.81 | TPSAB1 (0.65) | KMT2AALDH1A1MEN1USP2CA1 | |
| SCHEMBL11869640 | 0.80 | KMT2A (0.64) | KMT2AALDH1A1MEN1USP2TPSAB1 | |
| SCHEMBL6467130 | 0.80 | HPGD (0.73) | KMT2AALDH1A1MEN1KDM4ETPSAB1 | |
| SCHEMBL14679156 | 0.78 | TPSAB1 (0.62) | KMT2AALDH1A1MEN1USP2APEX1 | |
| SCHEMBL14344692 | 0.76 | TPSAB1 (0.61) | KMT2AALDH1A1MEN1USP2TDP1 | |
| SCHEMBL17335992 | 0.76 | CYP3A4 (0.63) | KMT2AALDH1A1MEN1USP2KDM4E | |
| SCHEMBL14679454 | 0.76 | KMT2A (0.59) | KMT2AALDH1A1MEN1USP2KDM4E | |
| SCHEMBL11295318 | 0.76 | HTT (0.63) | KMT2AALDH1A1MEN1TDP1HTT | |
| SCHEMBL5326701 | 0.74 | HTT (0.70) | KMT2AALDH1A1MEN1USP2TDP1 | |
| SCHEMBL18235894 | 0.74 | CA1 (0.62) | KMT2AALDH1A1MEN1KDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | WHITEFORD JEFFERY A (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | WHITEFORD JEFFERY A (US) | 2013-04-04 | — | — | US | disclosed |
| US-8182695-B2 | Bridged macrocyclic module compositions | WHITEFORD JEFFERY A (US) | 2012-05-22 | — | — | US | disclosed |
| US-8110679-B2 | Nanofilm and membrane compositions | COVALENT PARTNERS LLC (US) | 2012-02-07 | — | — | US | disclosed |
| US-20110172126-A1 | LIBRARIES OF PEPTIDE CONJUGATES AND METHODS FOR MAKING THEM | XENOME LTD (AU) | 2011-07-14 | — | — | US | disclosed |
| US-20110172126-A1 | LIBRARIES OF PEPTIDE CONJUGATES AND METHODS FOR MAKING THEM | XENOME LTD (AU) | 2011-07-14 | — | — | US | disclosed |
| US-7767810-B2 | Macrocyclic modules comprising linked cyclic synthon units for use in the formation of selectively permeable membranes | COVALENT PARTNERS, LLC (US) | 2010-08-03 | — | — | US | disclosed |
| US-7767810-B2 | Macrocyclic modules comprising linked cyclic synthon units for use in the formation of selectively permeable membranes | COVALENT PARTNERS, LLC (US) | 2010-08-03 | — | — | US | disclosed |
| WO-2010025510-A1 | LIBRARIES OF PEPTIDE CONJUGATES AND METHODS FOR MAKING THEM | XENOME LTD (AU) | 2010-03-11 | — | — | WO | disclosed |
| US-7595368-B2 | Nanofilm compositions with polymeric components | COVALENT PARTNERS, LLC (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090114596-A1 | NANOFILM AND MEMBRANE COMPOSITIONS | COVALENT PARTNERS LLC | 2009-05-07 | — | — | US | disclosed |
| US-20080290034-A1 | Bridged macrocyclic module compositions | COVALENT PARTNERS LLC | 2008-11-27 | — | — | US | disclosed |
| US-7449544-B2 | p21 peptides | CYCLACEL LIMITED (GB) | 2008-11-11 | — | — | US | disclosed |
| US-7449544-B2 | p21 peptides | CYCLACEL LIMITED (GB) | 2008-11-11 | — | — | US | disclosed |
| US-7432371-B2 | Nanofilm and membrane compositions | COVALENT PARTNERS, LLC (US) | 2008-10-07 | — | — | US | disclosed |
| US-7368564-B2 | Bridged macrocyclic module compositions | COVALENT PARTNERS, LLC (US) | 2008-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130081999-A1 | Bridged Macrocyclic Module Compositions | SBDS, NCL, INTS6 | KMT2A 3432/4885ALDH1A1 4017/4885MEN1 1259/4885 |
| US-20080290034-A1 | Bridged macrocyclic module compositions | SBDS, NCL, INTS6 | KMT2A 3294/4885ALDH1A1 3961/4885MEN1 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.